6.38
price down icon11.14%   -0.80
after-market アフターアワーズ: 6.38
loading
前日終値:
$7.18
開ける:
$6.64
24時間の取引高:
2.24M
Relative Volume:
1.77
時価総額:
$327.12M
収益:
$676.80M
当期純損益:
$-8.60M
株価収益率:
-22.55
EPS:
-0.2829
ネットキャッシュフロー:
$135.40M
1週間 パフォーマンス:
-9.63%
1か月 パフォーマンス:
-5.48%
6か月 パフォーマンス:
-25.99%
1年 パフォーマンス:
-32.13%
1日の値動き範囲:
Value
$6.1505
$6.73
1週間の範囲:
Value
$6.1505
$7.33
52週間の値動き範囲:
Value
$4.36
$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name
名前
Emergent Biosolutions Inc
Name
セクター
Healthcare (1052)
Name
電話
240-631-3200
Name
住所
300 PROFESSIONAL DR, GAITHERSBURG, MD
Name
職員
900
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
EBS's Discussions on Twitter

Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
EBS icon
EBS
Emergent Biosolutions Inc
6.38 327.12M 676.80M -8.60M 135.40M -0.2829
TAK icon
TAK
Takeda Pharmaceutical Co Adr
19.67 62.84B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
41.50 48.40B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
10.13 44.55B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
79.38 32.80B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
533.12 22.87B 3.17B 1.29B 1.01B 27.09

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-08-21 再開されました JP Morgan Underweight
2024-12-30 開始されました H.C. Wainwright Buy
2024-08-22 開始されました Rodman & Renshaw Buy
2024-03-07 アップグレード The Benchmark Company Hold → Buy
2023-11-20 再開されました JP Morgan Underweight
2023-08-29 ダウングレード The Benchmark Company Buy → Hold
2023-04-10 アップグレード The Benchmark Company Hold → Buy
2023-03-17 ダウングレード JP Morgan Neutral → Underweight
2022-11-10 ダウングレード The Benchmark Company Buy → Hold
2022-04-29 ダウングレード Cantor Fitzgerald Overweight → Neutral
2022-01-20 アップグレード The Benchmark Company Hold → Buy
2021-11-08 ダウングレード The Benchmark Company Buy → Hold
2021-05-05 ダウングレード Argus Buy → Hold
2021-04-07 開始されました The Benchmark Company Buy
2021-02-24 アップグレード Chardan Capital Markets Neutral → Buy
2021-02-19 ダウングレード Chardan Capital Markets Buy → Neutral
2021-01-08 ダウングレード Wells Fargo Overweight → Equal Weight
2020-09-14 再開されました JP Morgan Neutral
2020-07-31 繰り返されました Chardan Capital Markets Buy
2019-09-12 開始されました Guggenheim Buy
2019-09-04 アップグレード Wells Fargo Market Perform → Outperform
2018-11-02 アップグレード Goldman Neutral → Buy
2018-08-03 繰り返されました Chardan Capital Markets Buy
2018-06-13 開始されました Argus Buy
2018-04-25 ダウングレード Wells Fargo Outperform → Market Perform
2018-01-24 開始されました Goldman Neutral
2018-01-16 繰り返されました Chardan Capital Markets Buy
2016-06-28 繰り返されました Singular Research Buy
2016-04-15 開始されました Chardan Capital Markets Buy
2016-03-28 開始されました Singular Research Buy
2016-02-19 開始されました Wells Fargo Outperform
2014-05-15 開始されました Summer Street Research Buy
2011-05-31 繰り返されました WBB Securities Strong Buy
2011-01-10 繰り返されました Wedbush Outperform
2010-11-05 繰り返されました Wedbush Outperform
2010-08-18 アップグレード WBB Securities Buy → Strong Buy
2010-08-06 繰り返されました Caris & Company Buy
すべてを表示

Emergent Biosolutions Inc (EBS) 最新ニュース

pulisher
Oct 16, 2026

Emergent BioSolutions stock falls as CFO plans retirement - Investing.com

Oct 16, 2026
pulisher
Oct 16, 2026

Emergent BioSolutions CFO to retire, treasurer named interim - Investing.com

Oct 16, 2026
pulisher
Oct 16, 2026

Emergent BioSolutions Inc. Announces Chief Financial Officer Changes - marketscreener.com

Oct 16, 2026
pulisher
Oct 16, 2026

Emergent BioSolutions (EBS) CFO Richard Lindahl to Retire, Shares Drop Premarket - GuruFocus

Oct 16, 2026
pulisher
Oct 16, 2026

Emergent Biosolutions Announces Retirement of Richard S. Lindahl as Executive Vice President, Effective December 31, 2026 - www.marketscreener.com

Oct 16, 2026
pulisher
Oct 16, 2026

Emergent BioSolutions CFO Richard Lindahl to Retire, Frank Vargo Named Interim Successor - citybiz

Oct 16, 2026
pulisher
Oct 16, 2026

Emergent BioSolutions (EBS) CFO Richard Lindahl to Retire; Inter - GuruFocus

Oct 16, 2026
pulisher
Oct 16, 2026

Emergent BioSolutions CFO Richard Lindahl to retire end of 2026 - StreetInsider

Oct 16, 2026
pulisher
Oct 16, 2026

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl - Business Wire

Oct 16, 2026
pulisher
Oct 15, 2026

Press Release: Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 - Moomoo

Oct 15, 2026
pulisher
Oct 15, 2026

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 - Business Wire

Oct 15, 2026
pulisher
Oct 07, 2026

Emergent BioSolutions Director Donald W. DeGolyer Sells 17,800 Shares on October 7, 2026 - Kalkine Media

Oct 07, 2026
pulisher
Oct 07, 2026

Form 4 Emergent Biosolutions Inc For: 7 October By Investing.com - Investing.com Canada

Oct 07, 2026
pulisher
Oct 07, 2026

Emergent BioSolutions director DeGolyer sells $126k in shares - Investing.com

Oct 07, 2026
pulisher
Oct 07, 2026

Director Donald DeGolyer proposes selling 17,800 Emergent BioSolutions (NYSE: EBS) shares. - Stock Titan

Oct 07, 2026
pulisher
Oct 07, 2026

To cover stock-award taxes, an Emergent BioSolutions (EBS) director sold 17,800 shares under a trading plan. - Stock Titan

Oct 07, 2026
pulisher
Oct 06, 2026

EBS5025998 Bond Profile: Coupon and Redemption - TradingView

Oct 06, 2026
pulisher
Oct 06, 2026

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 06, 2026

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? - Yahoo Finance

Oct 06, 2026
pulisher
Oct 05, 2026

Form 4 Emergent Biosolutions Inc For: 5 October By Investing.com - Investing.com South Africa

Oct 05, 2026
pulisher
Oct 05, 2026

Emergent BioSolutions (EBS) SVP, Products Business Paul Williams Sells 3,000 Shares - GuruFocus

Oct 05, 2026
pulisher
Oct 05, 2026

Why is Emergent Biosolutions stock surging today? - Investing.com

Oct 05, 2026
pulisher
Oct 05, 2026

Emergent BioSolutions stock gains 7.11 percent on October 5 - AD HOC NEWS

Oct 05, 2026
pulisher
Oct 05, 2026

Emergent BioSolutions SVP Paul Williams sells $19,590 in stock - Investing.com

Oct 05, 2026
pulisher
Oct 05, 2026

Form 4 Emergent Biosolutions Inc For: 5 October By Investing.com - Investing.com UK

Oct 05, 2026
pulisher
Oct 05, 2026

Under a trading plan, Emergent BioSolutions (EBS) officer Williams sold 3,000 shares at $6.53. - Stock Titan

Oct 05, 2026
pulisher
Oct 01, 2026

Emergent BioSolutions Inc. Common Stock (NYSE:EBS) Detailed Stock Data - The Chronicle-Journal

Oct 01, 2026
pulisher
Oct 01, 2026

A 3,000-share sale is proposed by Emergent BioSolutions (EBS) officer Paul Williams. - Stock Titan

Oct 01, 2026
pulisher
Sep 26, 2026

Emergent BioSolutions Inc. (EBS) Investigation: Bronstein, Gewirt - The National Law Review

Sep 26, 2026
pulisher
Sep 25, 2026

Precision Trading with Emergent Biosolutions Inc. (EBS) Risk Zones - news.stocktradersdaily.com

Sep 25, 2026
pulisher
Sep 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - PR Newswire

Sep 24, 2026
pulisher
Sep 24, 2026

Emergent BioSolutions Inc (ER4.DU) Analyst insights, Price targets and RecommendationsYahoo Finance - Yahoo Finance Singapore

Sep 24, 2026
pulisher
Sep 22, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - GlobeNewswire Inc.

Sep 22, 2026
pulisher
Sep 22, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - FinancialContent

Sep 22, 2026
pulisher
Sep 20, 2026

Emergent BioSolutions stock steady as investors weigh recent fundamentals - AD HOC NEWS

Sep 20, 2026
pulisher
Sep 18, 2026

Emergent BioSolutions Inc. (EBS) Stock Analysis: Unpacking A 56.7% Potential Upside - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 17, 2026

Emergent BioSolutions restarts Massachusetts manufacturing after $34.5M vaccine deal - The Business Journals

Sep 17, 2026
pulisher
Sep 14, 2026

Emergent BioSolutions presents transformation update, Q2 results, $40M restructuring savings and revised FY26 guidance - TradingView

Sep 14, 2026
pulisher
Sep 09, 2026

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.

Sep 09, 2026
pulisher
Sep 08, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - GlobeNewswire Inc.

Sep 08, 2026
pulisher
Sep 08, 2026

Emergent Biosolutions Inc (EBS) Fundamental & Financial Data - Stocktwits

Sep 08, 2026
pulisher
Sep 06, 2026

Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha

Sep 06, 2026
pulisher
Sep 04, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Sep 04, 2026
pulisher
Sep 04, 2026

Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us

Sep 04, 2026
pulisher
Sep 04, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutio - The National Law Review

Sep 04, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com South Africa

Sep 03, 2026
pulisher
Sep 03, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Connect - ACCESS Newswire

Sep 03, 2026
pulisher
Sep 03, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioS - The National Law Review

Sep 03, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com Australia

Sep 03, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions Repurchases $75 Million of Debt at Discount - citybiz

Sep 03, 2026

Emergent Biosolutions Inc (EBS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Emergent Biosolutions Inc (EBS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
DeGolyer Donald W
Director
Oct 07 '26
Sale
7.09
17,800
126,202
111,921
Williams Paul Anthony
SVP, Products Business
Oct 01 '26
Sale
6.53
3,000
19,590
156,098
PAUL WILLIAMS
Officer
Oct 01 '26
Proposed Sale
6.53
3,000
19,592
0
Williams Paul Anthony
SVP, Products Business
Jul 01 '26
Sale
8.40
3,000
25,200
159,098
PAUL WILLIAMS
Officer
Jul 01 '26
Proposed Sale
8.40
3,000
25,205
0
DeGolyer Donald W
Director
May 01 '26
Sale
8.40
15,481
129,994
129,721
Zoon Kathryn C
Director
May 01 '26
Sale
8.40
17,202
144,453
79,941
SUJATA TYAGI DAYAL
Director
May 01 '26
Proposed Sale
8.40
13,761
115,612
0
KATHRYN ZOON
Director
May 01 '26
Proposed Sale
8.40
17,202
144,492
0
DONALD DEGOLYER
Director
May 01 '26
Proposed Sale
8.40
15,481
130,064
0
CGC CGC
$0.713
price down icon 3.06%
$3.19
price down icon 14.02%
$7.08
price down icon 6.84%
$19.98
price down icon 3.43%
ACB ACB
$3.99
price down icon 2.68%
$6.38
price down icon 0.93%
大文字化:     |  ボリューム (24 時間):